Jasper Therapeutics COO Matthew E. Ros files initial beneficial ownership statement
JSPR•Initial beneficial ownership filing
Jasper Therapeutics COO Matthew E. Ros reported stock options for 103,204 voting common shares at USD 0.01.
Related News
Domo Announces Agreement To Sell Substantially All Assets And Certain Liabilities
DOMO•
Marcus & Millichap brokers USD 10.8 million sale of 101-unit senior multifamily property in Willits, California
MMI•
Molina's profit forecast lift overshadowed by Obamacare weakness
MOH•
IBM cuts annual revenue growth forecast as customers prioritize AI infrastructure spending
IBM•
James Hardie updates financial calendar for Q1 FY27 earnings release and conference call
JHX•